Sun Pharma slips after Halol unit gets 10 observations from US FDA

10 May 2022 , 12:52 PM

The Gujarat-based facility of Sun Pharma was inspected by the United States Food and Drug Administration (US FDA) from 26 April to 9 May 2022. The company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days. The company is committed to addressing these observations promptly. The company remains committed to working closely with the US FDA and continues to enhance its GMP compliance on an ongoing basis,? Sun Pharma said in a statement. Sun Pharmaceutical Industries is the worlds fourth largest specialty generic pharmaceutical company and Indias top pharmaceutical company. The companys consolidated net profit grew 11.13% to Rs 2,058.80 crore on a 11.61% rise in total revenue from operations to Rs 9,863.06 crore in Q3 December 2021 over Q3 December 2020.Powered by Capital Market – Live News